MyoKardia, Inc. is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.
News & Events
A Small Molecule Inhibitor of Sarcomere Contractility Suppresses Hypertrophic Cardiomyopathy in Mice
MyoKardia Announces Presentations at American Heart Association Scientific Sessions 2015
MyoKardia Announces Closing of Initial Public Offering